AcNK-Sup003 cell is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase EARLY_PHASE1. The sponsor with the most trials is Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). The most-studied condition is B-cell Non-Hodgkin Lymphoma (B-NHL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma (B-NHL)
|
Phase EARLY_PHASE1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | China |
|
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT07345741 · ClinicalTrials.gov ↗ · R/R B-NHL, Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)
|
Not applicable | Not yet open | Donghua Zhang | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Donghua Zhang | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name AcNK-Sup003 cell as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) and Donghua Zhang (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how AcNK-Sup003 cell works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AcNK-Sup003 cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AcNK-Sup003 cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.